GlassScriptPhysician profile
Boris Shkolnik
NPI 1356608905
$208,851.35
in general payments reported to CMS, 2019-2025
24 companies · $53K in 2025
The $53K reported for 2025 was more than what 99% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $511 · 2020: $15K · 2021: $26K · 2022: $26K · 2023: $56K · 2024: $33K · 2025: $53K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $130K · Food and Beverage: $6,430 · Travel and Lodging: $2,404 · Consulting Fee: $2,235 · Education: $381 · Gift: $17.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $130,100.00 |
| Food and Beverage | $6,429.95 |
| Travel and Lodging | $2,403.55 |
| Consulting Fee | $2,235.00 |
| Education | $380.67 |
| Gift | $17.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $113,064.06 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $87,464.84 | 2022-2025 | Airsupra, Breztri, Tezspire |
| Genzyme Corporation | $5,972.68 | 2021-2023 | |
| Astellas Pharma US INC | $533.94 | 2020-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $352.49 | 2019-2025 | Ofev |
| Regeneron Healthcare Solutions, INC. | $344.35 | 2021-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $200.05 | 2019 | |
| Pulmonx Corporation | $147.97 | 2022 | |
| Chiesi USA, INC. | $142.17 | 2020-2023 | Bronchitol, Pertzye |
| Ethicon INC. | $130.83 | 2021 | |
| Amgen INC. | $124.46 | 2024 | Tavneos |
| Sanofi-Aventis U.S. LLC | $89.99 | 2024 | |
| Pfizer INC. | $46.73 | 2020-2021 | |
| Verona Pharma, INC. | $45.66 | 2025 | Ohtuvayre |
| Mylan Specialty L.P. | $44.18 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $31.55 | 2023-2024 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $27.15 | 2025 | Glassia |
| Electromed, INC. | $23.58 | 2025 | Smartvest |
| Viatris Specialty LLC | $22.09 | 2025 | |
| Insmed, INC. | $16.24 | 2023 | Arikayce |
| Phathom Pharmaceuticals, INC. | $14.64 | 2025 | Voquezna |
| Alexion Pharmaceuticals, INC. | $11.70 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Boris Shkolnik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.